NasdaqCM - Nasdaq Real Time Price
USD
Regencell Bioscience Holdings Limited (RGC)
6.71
-0.15
(-2.19%)
At close: 4:00:00 PM EDT
6.71
0.00
(0.00%)
After hours: 4:00:16 PM EDT
Trade RGC on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for RGC
What's happening with RGC?
Powered by Yahoo ScoutRegencell Bioscience reported a wider $11.7 million fiscal-year lossand no meaningful revenue. Coverage also points to a Department of Justice investigation, adverse internal-control findings, and an unusually high valuation based on reported price-to-book measures. RGC is down 2.19% in the current regular session on October 30, 2026.
Powered by Yahoo Scout
- Previous Close
6.86 - Open
6.89 - Bid 4.92 x 200
- Ask 8.49 x 200
- Day's Range
6.53 - 7.05 - 52 Week Range
4.51 - 69.00 - Volume
147,230 - Avg. Volume
249,901 - Market Cap (intraday)
3.327B - Beta (5Y Monthly) 1.17
- PE Ratio (TTM)
-- - EPS (TTM)
-0.02 - Earnings Date (est.) Oct 28, 2026
- Forward Dividend & Yield -- (0.00%)
- Ex-Dividend Date --
- 1y Target Est
--
Recent News
View MorePerformance Overview
Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
RGC
68.05%
S&P 500 (^GSPC)
10.73%
1-Year Return
RGC
58.96%
S&P 500 (^GSPC)
11.11%
3-Year Return
RGC
1,528.23%
S&P 500 (^GSPC)
81.91%
5-Year Return
RGC
1,798.59%
S&P 500 (^GSPC)
64.59%
Statistics
View MoreValuation Measures
As of 10/29/2026
-
Market Cap
3.39B
-
Enterprise Value
3.38B
-
Trailing P/E
--
-
Forward P/E
--
-
PEG Ratio (current)
--
-
Price/Sales (ttm)
--
-
Price/Book (mrq)
254.09
-
Enterprise Value/Revenue
--
-
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
-
Profit Margin
0.00%
-
Return on Assets (ttm)
-71.54%
-
Return on Equity (ttm)
-128.52%
-
Revenue (ttm)
--
-
Net Income Avi to Common (ttm)
-11.7M
-
Diluted EPS (ttm)
-0.02
Balance Sheet and Cash Flow
-
Total Cash (mrq)
14.19M
-
Total Debt/Equity (mrq)
2.22%
-
Levered Free Cash Flow (ttm)
-2.99M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
6.71
-2.19%
Mkt Cap
3.327B
Industry
Drug Manufacturers—Specialty & Generic
3.8900
-3.71%
Mkt Cap
488.24M
Industry
Drug Manufacturers—Specialty & Generic
3.2500
-8.45%
Mkt Cap
336,618
Industry
Drug Manufacturers—Specialty & Generic
27.68
-6.71%
Mkt Cap
6.458B
Industry
Drug Manufacturers—Specialty & Generic
42.09
+1.50%
Mkt Cap
49.089B
Industry
Drug Manufacturers—Specialty & Generic
2.5300
-4.17%
Mkt Cap
373.902M
Industry
Drug Manufacturers—Specialty & Generic
0.6525
-3.33%
Mkt Cap
293.168M
Industry
Drug Manufacturers—Specialty & Generic
2.5200
-3.82%
Mkt Cap
31.612M
Industry
Drug Manufacturers—Specialty & Generic
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
